Literature DB >> 2208162

Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures.

J M Watson1, J L Sensintaffar, J S Berek, O Martínez-Maza.   

Abstract

We examined the production and utilization of interleukin 6 (IL-6), a multifunctional cytokine with diverse biological effects, by both ovarian cancer cell lines and primary ovarian tumor cultures. We have found that epithelial ovarian cancer cell lines (CAOV-3, OVCAR-3, and SKOV-3) constitutively produce varying amounts of IL-6. This molecule is biologically active as determined by the proliferation of an IL-6-dependent hybridoma cell line, MH60.BSF-2, and is detectable by an IL-6 enzyme-linked immunosorbent assay. By cytoplasmic immunoperoxidase staining, greater than 98% of the cells produce at least some IL-6, with variation in the staining intensity between individual cells. The ovarian cancer cell-produced protein has a molecular weight of approximately 24,000, and exhibits some molecular weight heterogeneity, with Mr 27,000 and 28,000 minor forms of IL-6. The levels of IL-6 produced by ovarian cancer cells can be modulated by other inflammatory cytokines, such as tumor necrosis factor-alpha, interleukin-1 beta, and interferon-gamma. Our results suggest that IL-6 is not an autocrine growth factor for these established ovarian tumor cell lines, because the addition of either exogenous IL-6 or antibodies to IL-6 did not affect the cellular proliferation of the cell lines. We also found significant levels (greater than 3 ng/ml) of IL-6 in ascitic fluids of ovarian cancer patients and in the supernants of primary cultures from freshly excised ovarian tumors. The production of IL-6 by epithelial ovarian cancer cells may prove to be a useful diagnostic tool and aid in investigation of the host immune response to ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208162

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  Serum interleukin-6 and -10 levels in patients with gastric cancer.

Authors:  Masahide Ikeguchi; Tomoko Hatada; Manabu Yamamoto; Takanori Miyake; Tomonori Matsunaga; Youji Fukumoto; Yoshinori Yamada; Kenji Fukuda; Hiroaki Saito; Shigeru Tatebe
Journal:  Gastric Cancer       Date:  2009-06-27       Impact factor: 7.370

2.  Interleukin-6 and renal cell cancer: production, regulation, and growth effects.

Authors:  A S Koo; C Armstrong; B Bochner; T Shimabukuro; C L Tso; J B deKernion; A Belldegrum
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Fibronectin-fragment-induced cartilage chondrolysis is associated with release of catabolic cytokines.

Authors:  G A Homandberg; F Hui; C Wen; C Purple; K Bewsey; H Koepp; K Huch; A Harris
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

Review 4.  The pathogenesis of ovarian hyperstimulation syndrome: a continuing enigma.

Authors:  A Simon; A Revel; A Hurwitz; N Laufer
Journal:  J Assist Reprod Genet       Date:  1998-04       Impact factor: 3.412

Review 5.  Pre-treatment effects of peripheral tumors on brain and behavior: neuroinflammatory mechanisms in humans and rodents.

Authors:  Andrew Schrepf; Susan K Lutgendorf; Leah M Pyter
Journal:  Brain Behav Immun       Date:  2015-05-06       Impact factor: 7.217

6.  Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Fabio D'Antona; Ada-Maria Florena; Emanuele La Spada; Angela Terranova; Melchiorre Cervello; Natale D'Alessandro; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

7.  Normal and SV40 transfected human peritoneal mesothelial cells produce IL-6 and IL-8: implication for gynaecological disease.

Authors:  X Y Zhang; M Guckian; N Nasiri; P A Lovell; A G Dalgleish; D P J Barton
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

8.  Interleukin-6 and interleukin-6 receptor gene expression in pituitary tumors.

Authors:  A R Rezai; A Rezai; O Martínez-Maza; M Vander-Meyden; M H Weiss
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  CD38 expression as response of hematopoietic system to cancer.

Authors:  Işil Albeniz; Ozlem Demir-Coşkun; Leyla Türker-Şener; Aycan Baş; Oktar Asoğlu; Rüstem Nurten
Journal:  Oncol Lett       Date:  2011-05-16       Impact factor: 2.967

10.  Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer.

Authors:  Y Okugawa; C Miki; Y Toiyama; H Yasuda; T Yokoe; S Saigusa; J Hiro; K Tanaka; Y Inoue; M Kusunoki
Journal:  Br J Cancer       Date:  2010-09-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.